Recent Advances in Inflammation & Allergy Drug Discovery

metrics 2024

Pioneering research in inflammation and allergy therapeutics.

Introduction

Recent Advances in Inflammation & Allergy Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed open-access journal dedicated to the dynamic fields of drug discovery, immunology, and allergy. Since its inception in 2021, this journal has emerged as a crucial platform for disseminating groundbreaking research and innovative methodologies that drive forward our understanding of inflammatory processes and allergic diseases. With an ISSN of 2772-2708 and an E-ISSN of 2772-2716, it is currently indexed in various categories, boasting a Q3 ranking in Drug Discovery and Immunology & Allergy, and a Q1 ranking in Medicine (miscellaneous) for 2022. Operating from the United Arab Emirates, the journal aims to bridge the gap between laboratory research and clinical application, offering a comprehensive collection of articles that are accessible to a broad audience. Through its commitment to open access, it ensures that critical findings are widely available, fostering collaboration and innovation among researchers, practitioners, and students alike. Join the scholarly community engaged in this vital area of research and contribute to the ongoing advancements in inflammation and allergy therapeutics.

Metrics 2024

SCIMAGO Journal Rank0.44
Journal Impact Factor1.20
Journal Impact Factor (5 years)1.20
H-Index37
Journal IF Without Self1.20
Eigen Factor0.00
Normal Eigen Factor0.01
Influence0.21
Immediacy Index0.10
Cited Half Life-
Citing Half Life7.50
JCI0.24
Total Documents348
WOS Total Citations30
SCIMAGO Total Citations1996
SCIMAGO SELF Citations43
Scopus Journal Rank0.44
Cites / Document (2 Years)0.86
Cites / Document (3 Years)2.00
Cites / Document (4 Years)4.15

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #115/272
Percentile 57.72
Quartile Q2
Drug Discovery in Pharmacology, Toxicology and Pharmaceutics
Rank #89/157
Percentile 43.31
Quartile Q3
Immunology and Allergy in Medicine
Rank #137/233
Percentile 41.20
Quartile Q3

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 290/354
Percentile 18.20
Quartile Q4

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 306/354
Percentile 13.56
Quartile Q4

Quartile History

Similar Journals

CURRENT PHARMACEUTICAL DESIGN

Exploring Breakthroughs in Pharmacology and Drug Design
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1381-6128Frequency: 46 issues/year

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

INFLAMMOPHARMACOLOGY

Pioneering evidence-based approaches in pharmacological science.
Publisher: SPRINGER BASEL AGISSN: 0925-4692Frequency: 6 issues/year

INFLAMMOPHARMACOLOGY is a premier journal published by SPRINGER BASEL AG, specializing in the evolving fields of immunology and pharmacology. Established in 1991, the journal has made significant strides in contributing to the understanding of inflammation-related disorders, therapeutic innovations, and the pharmacological implications associated with these conditions. With an impressive Q2 ranking in Immunology and Q1 rankings in both Pharmacology and Medical Pharmacology for 2023, alongside notable Scopus rankings, INFLAMMOPHARMACOLOGY maintains its position at the forefront of scientific research. The journal provides a vital platform for researchers and practitioners to disseminate groundbreaking findings and explore novel approaches in therapeutics, reinforcing the importance of evidence-based medicine. Accessible exclusively through traditional subscription options, it continues to attract a diverse readership invested in advancing knowledge within these cutting-edge disciplines.

Annual Review of Pharmacology and Toxicology

Pioneering knowledge in pharmacology and toxicology.
Publisher: ANNUAL REVIEWSISSN: 0362-1642Frequency: 1 issue/year

Annual Review of Pharmacology and Toxicology is a leading journal published by ANNUAL REVIEWS, renowned for its comprehensive and critical reviews of the fields of pharmacology and toxicology. With an esteemed history spanning from 1965 to the present and an impressive Q1 ranking in both categories, this journal stands at the forefront of scholarly communication in pharmacological sciences. Researchers are encouraged to submit cutting-edge studies that advance knowledge and innovation in drug development, safety assessments, and therapeutic practices. Although this journal does not currently offer Open Access options, it remains a vital resource for professionals and students who seek to stay updated with the latest high-impact research findings. The journal is indexed in Scopus, boasting remarkable rankings, including Rank #1 in Toxicology and Rank #4 in Pharmacology, reflecting its pivotal role in shaping the discourse in these dynamic fields.

EXPERT OPINION ON THERAPEUTIC TARGETS

Transforming clinical biochemistry with expert-driven knowledge.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8222Frequency: 12 issues/year

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

ACS Pharmacology & Translational Science

Driving breakthroughs from bench to bedside.
Publisher: AMER CHEMICAL SOCISSN: Frequency: 12 issues/year

ACS Pharmacology & Translational Science is a premier journal published by the American Chemical Society, dedicated to advancing knowledge in the fields of pharmacology and translational science. Operating since 2018, the journal has quickly established itself as a leader in its domain, holding a prestigious Q1 ranking in both Pharmacology and Medical Pharmacology for 2023. With a robust Scopus ranking, it currently occupies the 21st position out of 272 in Medical Pharmacology, reflecting its significant impact within the scientific community at the 92nd percentile. The journal provides an open-access platform for researchers to disseminate innovative findings and viewpoints that bridge the gap between drug discovery and clinical application. In an era where translational research is critical for the success of pharmacological advances, ACS Pharmacology & Translational Science serves as an essential resource for scientists, professionals, and students eager to explore cutting-edge developments in drug development and therapeutic strategies. The journal is based in the United States, with a commitment to fostering collaboration and knowledge sharing across borders.

MEDICINAL RESEARCH REVIEWS

Driving Excellence in Molecular Medicine Research
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

BIOMEDICINE & PHARMACOTHERAPY

Transforming healthcare with impactful research.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0753-3322Frequency: 12 issues/year

BIOMEDICINE & PHARMACOTHERAPY is a distinguished journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, specializing in the essential fields of medicine and pharmacology. Established in 1982 and covering literature up to 2024, this journal is notably recognized for its impact, holding a prestigious Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, as well as a commendable position within the top 10% of its category based on Scopus rankings. Researchers and practitioners will find it serves as a vital resource for the latest advancements, innovations, and critical reviews in the life sciences and therapeutic practices. The journal emphasizes rigorous peer review and high-quality publications, aimed at facilitating knowledge dissemination in biomedicine and pharmacotherapy. Its commitment to excellence makes it an indispensable platform for contributors and readers alike who are engaged in improving health outcomes through pharmaceutical research and medical advances.

Translational Research

Transforming Science into Health Solutions
Publisher: ELSEVIER SCIENCE INCISSN: 1931-5244Frequency: 12 issues/year

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Pioneering Research for Tomorrow's Medicines
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0266Frequency: 32 issues/year

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

Drug Target Insights

Connecting Researchers to Transformative Drug Insights.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.